Viray, H.; Piper-Vallillo, A.J.; Widick, P.; Academia, E.; Shea, M.; Rangachari, D.; VanderLaan, P.A.; Kobayashi, S.S.; Costa, D.B.
A Real-World Study of Patient Characteristics and Clinical Outcomes in EGFR Mutated Lung Cancer Treated with First-Line Osimertinib: Expanding the FLAURA Trial Results into Routine Clinical Practice. Cancers 2024, 16, 1079.
https://doi.org/10.3390/cancers16061079
AMA Style
Viray H, Piper-Vallillo AJ, Widick P, Academia E, Shea M, Rangachari D, VanderLaan PA, Kobayashi SS, Costa DB.
A Real-World Study of Patient Characteristics and Clinical Outcomes in EGFR Mutated Lung Cancer Treated with First-Line Osimertinib: Expanding the FLAURA Trial Results into Routine Clinical Practice. Cancers. 2024; 16(6):1079.
https://doi.org/10.3390/cancers16061079
Chicago/Turabian Style
Viray, Hollis, Andrew J. Piper-Vallillo, Page Widick, Emmeline Academia, Meghan Shea, Deepa Rangachari, Paul A. VanderLaan, Susumu S. Kobayashi, and Daniel B. Costa.
2024. "A Real-World Study of Patient Characteristics and Clinical Outcomes in EGFR Mutated Lung Cancer Treated with First-Line Osimertinib: Expanding the FLAURA Trial Results into Routine Clinical Practice" Cancers 16, no. 6: 1079.
https://doi.org/10.3390/cancers16061079
APA Style
Viray, H., Piper-Vallillo, A. J., Widick, P., Academia, E., Shea, M., Rangachari, D., VanderLaan, P. A., Kobayashi, S. S., & Costa, D. B.
(2024). A Real-World Study of Patient Characteristics and Clinical Outcomes in EGFR Mutated Lung Cancer Treated with First-Line Osimertinib: Expanding the FLAURA Trial Results into Routine Clinical Practice. Cancers, 16(6), 1079.
https://doi.org/10.3390/cancers16061079
